Skip to main content
Figure 2 | BMC Pharmacology and Toxicology

Figure 2

From: A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits

Figure 2

Effect of CNX-010-49 on liver gluconeogenesis in primary mouse hepatocytes. Mouse primary hepatocytes were treated with glucose free media containing LPCF (5 mM Lactate, 5 mM Pyruvate, 1 μM cortisone, 10 μM of forskolin) with or without 1 μM of CNX-010-49 for 18 h. Post 18 h, glucose released in the media (A) and mRNA expression gluconeogenic markers G6PC and PEPCK (B & C) were measured as mentioned in Methods. All the values are expressed as Mean ± SEM. Statistical comparison was conducted by One-way ANOVA followed by Dunnett’s test (n = 6) (*P < 0.05, **P < 0.01 and ***P < 0.001).

Back to article page